What changed for Colorectal Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Colorectal Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 15 to 14 (-1)
- Trials recruiting worldwide 594 to 614 (+20)
- Late-stage (Phase 3) trials 59 to 61 (+2)
- Trials on record 3,871 to 3,997 (+126)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Colorectal Cancer in July 2026. Voxsanity tracks 6 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 76 trials tracked for Colorectal Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05609370 · results posted 30 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 113 participants in total across two phases. The early phase (Phase 1b) tested three different doses of a drug called alcestobart, combined with three other medicines (tislelizumab, bevacizumab, and a chemotherapy called fluoropyrimidine), in 25 people, mainly to track unwanted medical events. The later phase (Phase 2) enrolled 88 people with a type of cancer, dividing them into groups based on whether their tumour tested positive or negative for a protein called PD-L1 (a marker sometimes used to guide treatment decis...
-
NCT04607421 · results posted 11 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04607421) enrolled a total of 841 participants across several groups and phases. It was designed to test an experimental treatment called EC (enfortumab conjugate, used alone or combined with chemotherapy regimens) against standard chemotherapy in people with a specific type of cancer. The trial ran in three main stages: a safety lead-in phase with 57 people (30 in one group, 27 in another) to check for early signs of serious side effects; a main Phase 3 comparing three arms with a combined 637 participants; and a Cohort 3...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04403022 · results posted 3 June 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a robotic surgical system called the da Vinci SP being used for two types of bowel operations: a right colectomy (removal of part of the large bowel on the right side) and a lower anterior resection (removal of part of the lower bowel). A total of 60 people took part — 29 in the right colectomy group and 31 in the lower anterior resection group. The trial was measuring two main things: whether each operation could be completed as planned without needing to switch to a different surgical approach, and how many partici...
-
NCT01105169 · results posted 20 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 250 adults who were divided into four groups based on a genetic variation (a difference in a single point in their DNA) and whether they received magnesium supplements or a dummy pill (placebo). The two genetic groups were labelled "GG" and "GA/AA." In total, 77 and 78 people in the GG group were assigned to magnesium and placebo respectively, while 47 and 48 people in the GA/AA group were assigned to magnesium and placebo respectively. Most participants completed the 12-week study. The trial was measuring changes in...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05983367 · results posted 20 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 76 people in total — 38 in each group. All participants had a type of cancer being treated with a chemotherapy-and-antibody combination called FOLFIRI plus bevacizumab. One group also received an investigational drug called ompenaclid, while the other received a placebo (a dummy treatment) alongside the same chemotherapy. The trial was primarily measuring the proportion of participants whose tumours shrank or disappeared, and it also tracked how long people went without their disease getting worse, how long they survi...
-
NCT03377361 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03377361) enrolled a total of 299 participants across ten different groups. The trial was set up in multiple parts and looked at an investigational treatment across different dosing groups and combinations. The earlier parts of the trial (Parts 1 and 1A) focused on tracking certain types of medical events — including any new or worsening health issues, abnormal blood test results related to the thyroid and liver, and specific events considered "dose-limiting" (meaning reactions serious enough that they might require changi...
-
NCT02060188 · results posted 6 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 385 people across nine treatment groups, all receiving different combinations of immunotherapy drugs (nivolumab, ipilimumab, and others) for colorectal cancer. The trial was measuring what is called the "objective response rate" — that is, the percentage of participants whose tumours shrank by a meaningful amount or disappeared entirely, based on standardised imaging measurements. It is noted that zero participants were recorded as having "completed" the study in the formal sense, meaning all participants fell into th...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04008030 · results posted 22 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04008030) enrolled 839 people across three groups: 353 received nivolumab alone (Arm A), 354 received nivolumab combined with ipilimumab (Arm B), and 132 received standard chemotherapy chosen by their doctor (Arm C). The trial was measuring "progression-free survival" — that is, how long participants went without their disease getting worse or dying — comparing the immunotherapy options against each other and against chemotherapy, in people whose cancer had a specific genetic feature called MSI-H or dMMR. The reported dat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04827732 · results posted 11 September 2025
According to the results reported on ClinicalTrials.gov, this trial tested a type of targeted radiation therapy called proton therapy (specifically, hypofractionated pencil-beam scanning IMPT) in people whose cancer had returned to a previously treated area of the pelvis. The treatment was delivered in 5 sessions and tested at different dose levels (labelled Dose Level -1, 1, 2, and 3) to find the highest dose that could be given without causing too many serious side effects. A total of 15 people took part across all dose levels — 1 at Dose Level -1, 7 at Dose Level 1, 3 at Dose Level 2, and 4...
-
NCT05330429 · results posted 1 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05330429) involved 77 people in total across three groups. Ten participants joined an initial "safety run-in" group receiving a combination of three treatments: magrolimab, bevacizumab, and FOLFIRI (a chemotherapy regimen). After that, 44 people were randomly assigned to receive the same three-drug combination, while 23 people were randomly assigned to receive bevacizumab and FOLFIRI without magrolimab. The trial was measuring, among other things, how long participants went without their disease getting worse (called "prog...
-
NCT04625803 · results posted 17 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04625803) enrolled 64 participants, all of whom received a combination of chemotherapy, a PD-1 inhibitor (a type of immunotherapy drug), and apatinib (a targeted therapy drug). The trial was focused on people with a specific type of rectal cancer classified as MSS/pMMR — meaning the cancer cells have a particular molecular characteristic. The main thing the trial set out to measure was the "tumour regression rate," which refers to how much the tumour had shrunk or changed in the tissue examined after treatment, rated on a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04472429 · results posted 23 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04472429) enrolled 308 participants across two groups during its main randomised period: 154 people received retifanlimab (a type of immunotherapy drug) combined with chemotherapy, and 154 people received a placebo (an inactive substance) combined with chemotherapy. A third group of 69 participants later entered a separate open-label phase and received retifanlimab on its own — these were participants who had been in the placebo plus chemotherapy group. The trial was primarily measuring "progression-free survival," which m...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00574353 · results posted 9 May 2025
According to the results reported on ClinicalTrials.gov, 23 people took part in this trial, and all 23 completed it. The trial was looking at whether a special type of scan — called an F-FMISO PET scan — could be used as a non-invasive way to detect low oxygen levels (known as hypoxia) inside colorectal cancer tumours. The scan used a radioactive tracer called fluoromisonidazole (FMISO) to try to measure how the tumour was taking up and holding onto the tracer over time. The reported data shows that, of the 23 participants, 18 were successfully scanned using the F-FMISO PET imaging, while 5 w...
-
NCT05002608 · results posted 21 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05002608) looked at a Health Insurance Navigation Program. A total of 36 people took part — 17 in the "Navigation Intervention" group (who received the navigation program) and 19 in the "Enhanced Usual Care" group (who received a comparison level of support). The trial was measuring three main things: how acceptable participants found the navigation program, whether people's understanding of health insurance terms changed over five months, and how feasible the program was to deliver (meaning whether participants could comp...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02965703 · results posted 4 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02965703) enrolled 70 people across three groups: 29 in the aspirin-only group, 33 in the aspirin-plus-placebo group, and 8 in the placebo-only group. Not everyone finished the trial — 19, 28, and 6 people respectively completed it in each group. The trial was looking at changes in biological markers measured from bowel tissue samples, specifically the balance between two processes in cells: how quickly cells multiply (called proliferation) and how quickly they break down or die off (called apoptosis or necroptosis). These...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03516942 · results posted 17 February 2025
According to the results reported on ClinicalTrials.gov, this observational study (NCT03516942) enrolled 565 people who had been diagnosed with colon or rectal cancer and were being treated with the aim of curing the disease. Participants were asked to complete questionnaires about their financial situation and ability to work — at the start of the study (within 60 days of diagnosis), and then again at 3, 6, and 12 months. A total of 450 people submitted the initial baseline survey, and numbers fell over time, with 207 people completing both the baseline and the 12-month survey. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01652196 · results posted 5 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 56 participants, all of whom completed the study. Every participant received aflibercept combined with chemotherapy. The trial was primarily measuring how many participants were still alive and had not seen their disease get worse at the 15-month mark. It also tracked a number of secondary measures, including how many participants' tumours shrank or disappeared, how many were able to have surgery, how long participants went without their disease getting worse, and how long participants lived overall. The reported dat...
-
NCT03298945 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03298945) involved 2,239 people in total — 1,139 who were assigned to use a bowel preparation product called GoLytely, and 1,100 who were assigned to use a MiraLax-Gatorade preparation. All participants who started the trial were recorded as completing it. The trial was measuring two main things: how many people actually turned up for their scheduled colonoscopy and had their bowel preparation rated as "adequate" by the doctor performing the procedure, and how many people had at least one polyp (called an adenoma — a small...
-
NCT03095703 · results posted 24 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03095703) enrolled 4 participants, all of whom received a drug called sirolimus. Three participants completed the trial, while one did not finish. The trial was measuring changes in the size and number of intestinal polyps (small growths inside the bowel) over 6 months of treatment, as well as recording any unwanted side effects that occurred during that time. The reported data shows that for the primary outcome looking at changes in the size of marked polyps, three separate measurements were recorded for the group: 16, 4...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04456699 · results posted 2 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04456699) enrolled 335 people across three groups: 111 received a combination of olaparib and bevacizumab, 115 received olaparib alone, and 109 received bevacizumab combined with chemotherapy. The trial was primarily measuring how long participants went without their cancer growing or spreading — known as "progression-free survival" — as judged by an independent review team who did not know which treatment each person was receiving. The reported data shows that the median time before the cancer progressed (or death occurr...
-
NCT02943265 · results posted 6 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02943265), called Project CONNECT, involved three groups of participants. The main group — people with complex cancer histories who received care coordination through the Project CONNECT program — started with 648 participants, with 634 completing the study. A second group of 2,674 people was included as a historical (retrospective) comparison group of cancer survivors, of whom 2,092 were considered eligible after review. A third group of 1,000 people without cancer was also included for comparison purposes. The trial was...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04744831 · results posted 2 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04744831) enrolled 122 adults with a specific type of advanced bowel cancer (metastatic colorectal cancer) whose tumours produced high levels of a protein called HER2. Participants were split into two groups based on the dose of the study drug, T-DXd (also called trastuzumab deruxtecan): 82 people received the lower dose (5.4 mg/kg every three weeks) and 40 received the higher dose (6.4 mg/kg every three weeks). The trial's main goal was to measure how many participants' tumours shrank or disappeared — known as the objecti...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04068610 · results posted 15 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04068610) enrolled 59 people across three groups. Seven participants took part in Part 1, which tested a four-drug combination (FOLFOX, Bevacizumab, Durvalumab, and Oleclumab) and focused mainly on monitoring safety signals — things like serious unwanted medical events, significant changes in blood test results, and abnormal vital signs. The remaining 52 participants were split evenly into two groups in Part 2 (26 each): one group received FOLFOX plus Bevacizumab, and the other received the same four-drug combination from...
-
NCT01133990 · results posted 7 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT01133990) was designed in two stages. The first stage (Phase 1b) aimed to find a suitable dose of a medicine called E7820 when combined with a chemotherapy regimen called FOLFIRI, by looking at side effects and other safety-related measurements. The second stage (Phase 2) was intended to compare three groups — FOLFIRI alone, FOLFIRI combined with a medicine called Bevacizumab, and FOLFIRI combined with E7820 — measuring how long participants went without their disease getting worse. Only 5 people participated in the first...
-
NCT03750786 · results posted 26 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03750786) enrolled 490 people in total, split evenly into two groups of 245 — referred to here as Group A and Group B. The trial was measuring how tumours responded to treatment, how long it took before the disease worsened, and how long any response to treatment lasted. The reported data shows that none of the participants were recorded as having "completed" the study in the formal sense, with all 490 listed as "not completed" — though this may reflect how the trial's completion was defined and recorded rather than dropou...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04322539 · results posted 14 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04322539) enrolled 691 people with advanced colorectal cancer who had already tried other treatments. Participants were randomly assigned to receive either fruquintinib (a tablet medicine) plus best supportive care (461 people) or a placebo (a dummy pill) plus best supportive care (230 people). The trial was primarily measuring how long participants lived overall, and also tracked several secondary measures including how long it took for the cancer to progress on scans, how many participants saw their cancer shrink, and ho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03735407 · results posted 13 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03735407) involved 40 participants who all completed the study — none dropped out. The trial was testing a device called the C-Scan system (also referred to as the Check-Cap system), which is a capsule-based procedure intended as an alternative to colonoscopy for examining the bowel. The trial measured three things: whether any serious harmful events related to the device or procedure occurred, how well participants stuck to the study requirements, and how satisfied participants were with the experience compared to colonos...
-
NCT01011478 · results posted 16 August 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 406 people — 204 in a placebo group and 202 in a rosuvastatin (a cholesterol-lowering medication) group. The trial was looking at people who had previously had colon cancer, and it was measuring whether rosuvastatin had any effect on the development of new bowel polyps (small growths in the bowel that can sometimes become cancerous), new colorectal cancers, or a return of their original colon cancer. Most participants completed the study — 192 in the placebo group and 195 in the rosuvastatin group. The reported data...
-
NCT02728804 · results posted 26 January 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 380 people who were receiving cancer treatment. All participants were asked to fill in questionnaires tracking the financial impact of their treatment over 12 months. Of the 380 who started, 368 completed the first questionnaire, and 269 finished the full study. The trial was not testing a medicine or procedure — instead, it was measuring how often cancer treatment led to serious financial hardship, and whether that differed depending on a person's age, race, marital status, employment, or income. The reported data s...
-
NCT01079780 · results posted 10 June 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT01079780) enrolled 136 participants across three treatment groups: Arm A (70 people), Arm B (16 people), and Arm C (50 people). The trial was measuring how different chemotherapy combinations affected people with cancer, looking mainly at how long participants lived without their disease getting worse (called "progression-free survival"). It also tracked whether tumours shrank, how long participants survived overall, and how many experienced serious side effects linked to treatment. The reported data shows that for the ma...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 76 reported results for Colorectal Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, colorectal cancer currently attracts a very large amount of public research funding in the United States, and that investment has remained broadly steady from year to year. For patients, this suggests that colorectal cancer is an established and sustained priority for publicly funded science, meaning researchers are continuously working to better understand the disea...
See the full Colorectal Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.